Teva Q1 revenue $3.7B flat YoY; non-GAAP EPS $0.40 down from $0.55; reaffirms FY 2023 outlook

TEVA PHARMACEUTICAL INDUSTRIES LTD

2023-Q1 EPS reported -$0.18 revenue$3,661,000,000

Revenues $3,661M flat YoY (up 4% local currency); GAAP loss per share ($0.18) improved from ($0.86).
Non-GAAP diluted EPS $0.40 vs $0.55 YoY; adjusted EBITDA $899M, down 21% from $1,135M.
Non-GAAP gross margin 49.1%, down from 54.2% due to inflationary pressures and unfavorable mix.
AUSTEDO grew 10% YoY and AJOVY grew 35% (local currency); UZEDY approved for schizophrenia.
Full-year 2023 outlook reaffirmed: revenue $14.8-15.4B, non-GAAP EPS $2.25-2.55, free cash flow $1.7-2.1B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2023 results: revenue $3,661 million, EPS GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40. Guidance reaffirmed.

Period: the quarter ended March 31, 2023
Revenue: $3,661 million
EPS: GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40
Guidance: reaffirmed
Result: reported results

Exact text from the filing

where we will make decisive choices and focus our resources to drive growth and innovation." First Quarter 2023 Consolidated Results Revenues in the first quarter of 2023 were $3,661 million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and

View on SEC.gov

Browse all earnings releases →

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001157523-23-000797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.